Introduction
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the first-line treatment of choice for patients with EGFR-mutant lung cancer. Interstitial lung disease (ILD) is an infrequent, yet significant, adverse effect of EGFR-TKI therapy. Erlotinibinduced ILD occurs in approximately 1% of patients treated. 1, 2 The clinical manifestations of pneumonitis can vary but include acute-onset dyspnea, cough, and fever. The radiologic presentation often consists of diffuse, multifocal, ground-glass and confluent opacities with intralobular interstitial thickening. 3 The histologic presentation varies but can present as diffuse alveolar damage, interstitial pneumonia, interstitial fibrosis, eosinophilic pneumonia, or bronchiolitis obliterans organizing pneumonia. 4 Because drug-induced pneumonitis can be progressive and fatal, early recognition of the symptoms and discontinuation of the offending drug are critical. Corticosteroids can sometimes be used to hasten resolution of the symptoms.
After the development of drug-induced pneumonitis, clinicians are often hesitant to readminister the offending agent or a similar medication in the same class. If pneumonitis occurs with a specific EGFR-TKI, 1 option is to consider rechallenge with another EGFR-TKI. Several case reports have described this, most often using a different EGFR-TKI at a lower dose with concurrent corticosteroids (Table 1) . No cases of afatinib rechallenge after erlotinib-induced ILD have been reported.
Case Report
A 61-year-old woman who had never smoked was diagnosed with stage IV EGFR-mutant lung adenocarcinoma that was metastatic to the lymph nodes, contralateral lung, and pleura ( Figure 1A ). She began treatment with erlotinib after her diagnosis. The initial scans demonstrated a response to treatment. Five months later, she had developed night sweats and a dry productive cough. Repeat computed tomography (CT) of her chest revealed her disease to be decreased but new patchy ground glass opacities were present throughout the right lung and left upper lobe ( Figure 1B ). She underwent bronchoscopy, and pathologic examination indicated an organizing pneumonia with focal non-necrotizing granulomas and chronic interstitial pneumonitis ( Figure 2 ). All infectious cultures were negative, and the biopsy results were consistent with drug-induced pneumonitis.
The patient subsequently stopped erlotinib and started prednisone 40 mg daily. She experienced an initial improvement in her clinical symptoms and on her CT scan ( Figure 1C ). She was then weaned off steroids because of side effects. A repeat CT scan, approximately 1 year after the diagnosis, demonstrated worsening
Clinical Practice Points Clinical Practice Points
Pneumonitis is a uncommon but serious complication of treatment with EGFR tyrosine kinase inhibitors. This is a case report of a successful rechallenge using afatinib after erlotinib-induced pneumonitis.
A retrial of the same or an alternate EGFR-TKI under careful observation may be warranted.
left lower lobe opacities and bilateral enlarging pulmonary nodules, consistent with disease progression ( Figure 1D ). She was then started on afatinib 40 mg daily. After starting afatinib, she felt better, with resolution of her cough and dyspnea on exertion occurring almost immediately. A repeat CT scan after 4 weeks showed a disease response to the treatment, with no recurrence of the inflammatory infiltrates ( Figure 1E ). At the last follow-up examination, she has continued afatinib with stable disease almost 3 years after her diagnosis of metastatic disease. The patient agreed to the description of her case in our report.
Conclusion
We have reported a case of a patient with biopsy-proven erlotinib-induced ILD who symptomatically improved after discontinuation of erlotinib and the initiation of corticosteroids. She subsequently received afatinib with good control of her disease and no recurrence of pneumonitis. We present a single case report, which limits any definitive conclusions. Because pneumonitis is seen as an idiopathic inflammatory response to a specific drug, it does not always recur with retrial of a similar Successful Retrial With Afatinib After Erlotinib-Induced Pneumonitis agent, such as described in the present report and in further examples in Table 1 , or the original offending agent. Dasatinib and erlotinib have been successfully reintroduced after pneumonitis at a lower dose. 8, 10 The risk of pneumonitis varies among the EGFR-TKIs, ranging from 0.8% with erlotinib to 2.4% with osimertinib and should be considered when choosing a subsequent drug for retrial. 11, 12 For patients with EGFR-TKIeinduced pneumonitis, a retrial of a different EGFR-TKI might be warranted in the setting of close supervision and follow-up protocols. Prospective data are needed to establish the safety of this clinical practice. 
